Emergent BioSolutions (EBS) downgraded to Hold as Narcan sales slip, competition rises and debt persists; review risks, cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results